So on that note, DKSH Holdings (Malaysia) Berhad (KLSE:DKSH) looks quite promising in regards to its trends of return on capital. If you haven't worked with ROCE before, it measures the 'return ...

Revenue: RM7.94b (up 5.6% from FY 2023). Net income: RM123.1m (up 11% from FY 2023). Profit margin: 1.6% (up from 1.5% in FY 2023). The increase in margin was driven by higher revenue. Looking ...

So on that note, DKSH Holdings (Malaysia) Berhad (KLSE:DKSH) looks quite promising in regards to its trends of return on capital. If you haven't worked with ROCE before, it measures the 'return' ...

Revenue: RM7.94b (up 5.6% from FY 2023). Net income: RM123.1m (up 11% from FY 2023). Profit margin: 1.6% (up from 1.5% in FY 2023). The increase in margin was driven by higher revenue. EPS: RM0.78 (up ...

particularly across Peninsular Malaysia and Sabah and Sarawak,” said Daniel Schwalb, vice-president of FMCG at DKSH Malaysia. He told StarBiz that DKSH’s vast consumer data allowed the company ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Under no circumstances this document is to be used or considered as an offer to sell, or a solicitation of any offer to buy, any security. While information contained herein has been obtained from ...

Alvotech acquires Xbrane’s R&D operations and the biosimilar candidate XB003. Xbrane retains some pre-clinical development programs, that it intends to commercialize, and will continue operating as a ...

“The FDA's filing acceptance of Dr. Reddy's proposed denosumab biosimilar marks an important milestone in bringing this biosimilar medication to more patients throughout the U.S.,” said Milan ...